<DOC>
	<DOCNO>NCT00295607</DOCNO>
	<brief_summary>This exploratory study evaluate impact eliminate steroid administration upon viral HCV load 12 month measure quantitative serum HCV-RNA determination patient transplant HCV cirrhosis .</brief_summary>
	<brief_title>Comparing Efficacy Safety Tacrolimus With Steroids Monoclonal Anti-IL2R Antibody Hepatitis C Virus ( HCV ) Positive Liver Transplant Patients</brief_title>
	<detailed_description>A comparison make two regimen include tacrolimus , one utilize standard steroid administration second daclizumab ( MAB ) avoid steroid prophylactic administration anti-rejection treatment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients 18 65 year age undergo primary orthotopic liver split liver allograft transplantation HCVcirrhosis eligible study . Patients receive cadaveric liver transplant compatible ABO blood type include . Recipient multiorgan transplant Recipient auxiliary graft Patient receive ABO incompatible graft Patients require immunosuppressive treatment Patients require ongoing corticosteroid therapy . Patient significant , uncontrolled concomitant infection and/or severe diarrhoea , vomit , active upper gastrointestinal tract malabsorption active peptic ulcer . Patient donor know HIV positive . Patient allergic intolerant study medication Patient pregnant breastfeeding . Patient previously enrol study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Liver Transplantation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Adult</keyword>
	<keyword>Treatment Outcome</keyword>
</DOC>